Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype?
Thura Win HtutKyaw Zin TheinKyaw Lwin AungThein Hlaing OoPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)
Thrombosis is the second leading cause of death in cancer patients. Patients with pancreatic cancer (PC) have a very high risk of developing venous thromboembolism (VTE). Even though primary ambulatory thromboprophylaxis (PATP) could decrease this risk, there are uncertain issues with regard to the choice and dose of anticoagulants, duration of anticoagulant therapy, and patient selection criteria. In addition, the current practice guidelines on PATP in PC patients are equivocal. This review critically appraises the evidence on the use of PATP in PC patients receiving chemotherapy.
Keyphrases
- venous thromboembolism
- direct oral anticoagulants
- end stage renal disease
- blood pressure
- ejection fraction
- chronic kidney disease
- newly diagnosed
- locally advanced
- healthcare
- peritoneal dialysis
- pulmonary embolism
- squamous cell carcinoma
- prognostic factors
- clinical practice
- mesenchymal stem cells
- quality improvement
- rectal cancer